ClinicalTrials.gg
CompletedNCT06995001Updated May 29, 2025

Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

A Phase 1 interventional study of SHR-2173 and SHR-2173 ;Placebo in Healthy Volunteers, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Apr 2024, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics and immunogenicity of a single dose of SHR-2173 by subcutaneous injection.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female between the ages of 18 and 45 years, inclusive;
  2. At least 50.0 kg for male subjects, 45.0 kg for female subjects, with a (BMI) between 19.0-28.0 kg/m2 , inclusive (BMI = weight/height2 );
  3. Female subjects of or male subjects whose partners are women of childbearing must avoid sperm/ovum donation and adopt highly effective measurements (non-pharmacological contraception is required during the trial period) from the time of signing the form until the final visit;
  4. Subjects who could understand the details, procedures, and possible adverse reactions of the trial before it begins and voluntarily sign a written informed consent form。

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of drug allergies, or those with an allergic constitution (e.g., allergic to two or more drugs, foods, or pollens), or those known to be allergic to the drug (including ) or similar drugs;
  2. History or presence of any condition that may affect the safety or the pharmacokinetics of the investigational drug, including: immune system, respiratory system, hematological system (e.g., hemolytic reactions), circulatory system, digestive system, urinary system, nervous system, endocrine system, psychiatric disorders, metabolic disorders, or other conditions deemed unsuitable for participation in clinical trials;
  3. Presence of active infection;
  4. History of severe herpes virus infection, or history or presence of malignant tumors;
  5. History of risk factors for torsades de pointes ventricular tachycardia, such as unexplained syncope, confirmed long syndrome (including family history), heart failure, myocardial infarction, or angina pectoris;
  6. Subjects who have undergone major surgery within 3 months prior to screening, or surgery that may significantly affect the pharmacokinetics or safety evaluation of the investigational drug, or those planning to undergo surgery during the trial period.
  7. Subjects who have used or are currently using any prescription drugs, over-the-counter medications, functional vitamins, health supplements, or herbal products within 2 weeks prior to dosing; or those planning to use other drugs during the trial period;
  8. Subjects who have been vaccinated within 30 days prior to dosing or plan to be vaccinated within 3 months after dosing.
  9. Subjects with a 12-lead showing first-degree or higher atrioventricular block, atrial fibrillation or flutter, QTcF ≥450 ms, or other abnormalities as judged by the investigator during the screening period;
  10. Subjects with clinically significant abnormalities in blood routine, urinalysis, blood biochemistry, coagulation function, physical examination, vital signs, chest X-ray, or abdominal ultrasound as judged by the investigator during the screening period;
  11. Subjects with positive results for surface antigen, virus antibody, Treponema pallidum antibody, or (HIV) during the screening period;
  12. Pregnant or lactating females, or subjects with a positive serum pregnancy test;
  13. Subjects with a positive tuberculosis infection screening test (interferon-gamma release assay, IGRA); IGRA includes but is not limited to QuantiFERON-TB Gold In-Tube (QFT-GIT) and T-SPOT.TB. If the IGRA result is indeterminate, retesting is allowed. Subjects with two indeterminate results will be considered positive.
  14. Subjects who participated in other clinical trials and used investigational drugs within 3 months prior to dosing, or whose last study ended less than 5 half-lives or the duration of biological effects (whichever is longer);
  15. Subjects who donated blood or lost ≥200 mL of blood (excluding menstrual blood loss in females) within 3 months prior to dosing, or received blood transfusions or blood products, or donated within 2 weeks prior to dosing, or plan to donate blood during or within 3 months after the trial;
  16. Subjects who frequently consumed alcohol (i.e., more than 14 standard units per week [1 standard unit = 14 g of alcohol, e.g., 360 mL beer, 45 mL of 40% spirits, or 150 mL wine]) within 3 months prior to dosing, or cannot abstain from alcohol during the trial period; or subjects with a positive breath alcohol test at baseline;
  17. Subjects with a history of drug abuse or illicit drug use, or a positive drug abuse screening test at baseline;
  18. Subjects who smoked more than 5 cigarettes or equivalent tobacco products daily within 3 months prior to dosing;
  19. Subjects with abnormalities at the injection site, as judged by the investigator to be unsuitable for subcutaneous administration;
  20. Any other reasons deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR-2173

  • Experimental
    Treatment group B

    Drug: SHR-2173 ;Placebo

  • Experimental
    Treatment group C

    Drug: SHR-2173 ;Placebo

  • Experimental
    Treatment group D

    Drug: SHR-2173 ;Placebo

  • Experimental
    Treatment group E

    Drug: SHR-2173 ;Placebo

Interventions

  • SHR-2173 injection dose 1;

  • DrugSHR-2173 ;Placebo

    SHR-2173 injection dose 2 ;Pacebo dose 2

  • DrugSHR-2173 ;Placebo

    SHR-2173 injection dose 3 ;Pacebo dose 3

  • DrugSHR-2173 ;Placebo

    SHR-2173 injection dose 4 ;Pacebo dose 4

  • DrugSHR-2173 ;Placebo

    SHR-2173 injection dose 5 ;Pacebo dose 5

06

What researchers measure

Primary outcomes

  1. Treatment-emergent Adverse Events (TEAE)

    Time frame: Day1~Day71

Secondary outcomes

  1. Cmax

    Time frame: Day1~Day71

  2. AUC0-t

    Time frame: Day1~Day71

  3. AUC0-∞

    Time frame: Day1~Day71

  4. Tmax,

    Time frame: Day1~Day71

  5. t1/2,

    Time frame: Day1~Day71

  6. CLz/F,

    Time frame: Day1~Day71

  7. Vz/F,

    Time frame: Day1~Day71

  8. Immunogenicity :Anti- SHR -2173 antibody (ADA)

    Time frame: Day1~Day71

07

Study locations

1 site
  • Haikou People's Hospital
    Haikou, Hainan 570208, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Nov 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 29, 2025
StartActual
Apr 28, 2024
Primary completionActual
Nov 28, 2024
CompletionActual
Nov 28, 2024
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06995001
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Apr 28, 2024
Primary completion
Nov 28, 2024
Completion
Nov 28, 2024
Last update
May 29, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2173

Start the discussion